Zolmitriptan

From Wikipedia, the free encyclopedia



Zolmitriptan
Systematic (IUPAC) name
(4S)-4-{[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl}- 1,3-oxazolidin-2-one
Identifiers
CAS number	139264-17-8
ATC code	N02CC03
PubChem	60857
DrugBank	APRD00376
Chemical data
Formula	C₁₆H₂₁N₃O₂
Mol. mass	287.357 g/mol
Pharmacokinetic data
Bioavailability	40% (oral)
Protein binding	25%
Metabolism	?
Half life	3 hours
Excretion	Renal (65%) and fecal (35%)
Therapeutic considerations
Pregnancy cat.	B3(AU) C(US)
Legal status	℞-only(US)
Routes	Oral, nasal spray

Zolmitriptan is an oral, selective serotonin 1B/1D (5-HT_1B/_1D) receptor agonist. It is a second-generation triptan, used in the acute treatment of migraine attacks with or without aura and cluster headaches.

Zolmitriptan is marketed by AstraZeneca with the brand names Zomig, Zomigon (Greece & Argentina) and AscoTop (Germany). In 2005, AstraZeneca generated $352 million in sales with Zomig.^{[citation needed]}

1 Description
2 Indications
3 Contraindications and precautions
4 Adverse reactions
5 References
6 External links

[edit] Description

Zolmitriptan is a synthetic tryptamine derivative and appears as a white powder that is readily soluble in water.

[edit] Indications

Zolmitriptan is used for the acute treatment of migraines with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine.

Zolmitriptan comes in both a swallowable and oral disintegrating tablet. People who get migraines from aspartame should not use the disintegrating tablet (Zomig ZMT), which contains aspartame.

[edit] Contraindications and precautions

Zolmitriptan should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's angina, or other significant underlying cardiovascular disease.

Zolmitriptan may increase blood pressure, it should not be given to patients with uncontrolled hypertension, should not be used within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide, and should not be administered to patients with hemiplegic or basilar migraine.

Concurrent administration of MAOI or use of zolmitriptan within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated.